A Randomized Controlled Trial Comparing Efficacy of Pentoxifylline and Pioglitazone on Metabolic Factors and Liver Histology in Patients with Non-alcoholic Steatohepatitis

Journal of Clinical and Experimental Hepatology

Volumn 2, Issue 4, 2012, Pages 333-337

  Sharma, Barjesh C ^a   Kumar, Ajay ^a   Garg, Vishal ^a   Reddy, Ravi S ^a   Sakhuja, Puja ^a   Sarin, Shiv K ^a  

^a G B PANT HOSPITAL   (India)

Author keywords

Metabolic syndrome; NASH; Nonalcoholic fatty liver disease; Pentoxyfylline; Pioglitazone

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; C PEPTIDE; INSULIN; LEPTIN; PENTOXIFYLLINE; PIOGLITAZONE; PROTON PUMP INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ACUTE DISEASE; ADULT; ARTICLE; CALORIC INTAKE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; FOOT EDEMA; FRACTURE; HEART FAILURE; HEARTBURN; HEPATITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CELL DAMAGE; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER HISTOLOGY; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEATOSIS; WALKING;

EID: 84871045264     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/j.jceh.2012.10.010     Document Type: Article

References (18)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231.
2. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., McCullough A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
3. Sanyal A.J., Campbell-Sargent C., Mirshahi F., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183-1192.
4. Kern P.A., Ranganathan S., Li C., Wood L., Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001, 280:E745-E751.
5. Schaffler A., Scholmerich J., Buchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue-emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005, 2:273-280.
6. Crespo J., Cayon A., Fernandez-Gil P., et al. Gene expression of tumor necrosis factor alfa and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001, 34:1158-1163.
7. Satapathy S.K., Sakhuja P., Malhotra V., Sharma B.C., Sarin S.K. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007, 22(5):634-638.
8. Satapathy S.K., Garg S., Chauhan R., et al. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004, 99:1946-1952.
9. Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
10. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetalogia 1985, 28:412-419.
11. Mofrad P., Contos M.J., Haque M., et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003, 37:1286-1292.
12. Promrat K., Lutchman G., Uwaifo G.I., et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004, 39:188-196.
13. Belfort R., Harrison S.A., Brown K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355:2297-2307.
14. Brunt E.M., Janney C.G., Di Bisceglie A.M., Neuschwander-Tetri B.A., Bacon B.R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94:2467-2474.
15. Lam Brian P., Younossi Zobair M. Treatment regimens for non-alcoholic fatty liver disease. Ann Hepatol 2009, 8(1):S51-S59.
16. Sanyal A.J., Chalasani N., Kowdley K.V., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 6, 362(18):1675-1685.
17. Adams L.A., Sanderson S., Lindor K.D., et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005, 42:132-138.
18. Berg A.H., Combs T.P., Scherer P.E. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002, 13:84-89.